Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia

Mol Psychiatry. 2022 Sep;27(9):3583-3591. doi: 10.1038/s41380-022-01649-w. Epub 2022 Jun 10.

Abstract

Dopamine (DA) and glutamate neurotransmission are strongly implicated in schizophrenia pathophysiology. While most studies focus on contributions of neurons that release only DA or glutamate, neither DA nor glutamate models alone recapitulate the full spectrum of schizophrenia pathophysiology. Similarly, therapeutic strategies limited to either system cannot effectively treat all three major symptom domains of schizophrenia: positive, negative, and cognitive symptoms. Increasing evidence suggests extensive interactions between the DA and glutamate systems and more effective treatments may therefore require the targeting of both DA and glutamate signaling. This offers the possibility that disrupting DA-glutamate circuitry between these two systems, particularly in the striatum and forebrain, culminate in schizophrenia pathophysiology. Yet, the mechanisms behind these interactions and their contributions to schizophrenia remain unclear. In addition to circuit- or system-level interactions between neurons that solely release either DA or glutamate, here we posit that functional alterations involving a subpopulation of neurons that co-release both DA and glutamate provide a novel point of integration between DA and glutamate systems, offering a key missing link in our understanding of schizophrenia pathophysiology. Better understanding of mechanisms underlying DA/glutamate co-release from these neurons may therefore shed new light on schizophrenia pathophysiology and lead to more effective therapeutics.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Corpus Striatum
  • Dopamine* / physiology
  • Glutamic Acid
  • Humans
  • Schizophrenia*
  • Synaptic Transmission / physiology

Substances

  • Dopamine
  • Glutamic Acid